Global Next Generation Cancer Diagnostics Market Overview:
Global Next Generation Cancer Diagnostics Market Is Expected to Grow at A Significant Growth Rate, And the Forecast Period Is 2025-2032, Considering the Base Year As 2024.
Global Next Generation Cancer Diagnostics Market Report 2025 comes with the extensive industry analysis with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2025-2032.This research study of Next Generation Cancer Diagnostics involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Next Generation Cancer Diagnostics Market:
The Next Generation Cancer Diagnostics Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for Next Generation Cancer Diagnostics Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Next Generation Cancer Diagnostics Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, Next Generation Cancer Diagnostics market has been segmented into:
qPCR & Multiplexing
Next Generation Sequencing
LOAC & RT-PCR
Other Technologies
By Application, Next Generation Cancer Diagnostics market has been segmented into:
Therapeutic Monitoring
Companion Diagnostics
Prognostics
Cancer Screening
Risk Analysis
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Next Generation Cancer Diagnostics market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Next Generation Cancer Diagnostics market.
Top Key Players Covered in Next Generation Cancer Diagnostics market are:
Abbott
Agilent Technologies
Almac Group
Cepheid
F. Hoffmann-La Roche Ltd
GE Healthcare
Genomic Health
Hologic
Illumina
Janssen Global Services
Koninklijke Philips N.V
Myriad Genetics
Novartis AG
Opko Health
PerkinElmer
Qiagen
Sysmex Corporation
Thermo Fisher Scientific
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Industry Dynamics and Opportunity Analysis
3.1.1 Growth Drivers
3.1.2 Limiting Factors
3.1.3 Growth Opportunities
3.1.4 Challenges and Risks
3.2 Market Trend Analysis
3.3 Strategic Pestle Overview
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Mapping
3.6 Regulatory Framework
3.7 Princing Trend Analysis
3.8 Patent Analysis
3.9 Technology Evolution
3.10 Investment Pockets
3.11 Import-Export Analysis
Chapter 4: Next Generation Cancer Diagnostics Market Type
4.1 Next Generation Cancer Diagnostics Market Snapshot and Growth Engine
4.2 Next Generation Cancer Diagnostics Market Overview
4.3 qPCR & Multiplexing
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 qPCR & Multiplexing: Geographic Segmentation Analysis
4.4 Next Generation Sequencing
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.4.3 Next Generation Sequencing: Geographic Segmentation Analysis
4.5 LOAC & RT-PCR
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.5.3 LOAC & RT-PCR: Geographic Segmentation Analysis
4.6 Other Technologies
4.6.1 Introduction and Market Overview
4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.6.3 Other Technologies: Geographic Segmentation Analysis
Chapter 5: Next Generation Cancer Diagnostics Market Application
5.1 Next Generation Cancer Diagnostics Market Snapshot and Growth Engine
5.2 Next Generation Cancer Diagnostics Market Overview
5.3 Therapeutic Monitoring
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Therapeutic Monitoring: Geographic Segmentation Analysis
5.4 Companion Diagnostics
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.4.3 Companion Diagnostics: Geographic Segmentation Analysis
5.5 Prognostics
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.5.3 Prognostics: Geographic Segmentation Analysis
5.6 Cancer Screening
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.6.3 Cancer Screening: Geographic Segmentation Analysis
5.7 Risk Analysis
5.7.1 Introduction and Market Overview
5.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.7.3 Risk Analysis: Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 Next Generation Cancer Diagnostics Market Share by Manufacturer (2025)
6.1.3 Concentration Ratio(CR5)
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 ABBOTT; AGILENT TECHNOLOGIES; ALMAC GROUP; CEPHEID; F. HOFFMANN-LA ROCHE LTD; GE HEALTHCARE; GENOMIC HEALTH; HOLOGIC; ILLUMINA; JANSSEN GLOBAL SERVICES; KONINKLIJKE PHILIPS N.V; MYRIAD GENETICS; NOVARTIS AG; OPKO HEALTH; PERKINELMER; QIAGEN; SYSMEX CORPORATION; THERMO FISHER SCIENTIFIC
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Operating Business Segments
6.2.5 Product Portfolio
6.2.6 Business Performance
6.2.7 Key Strategic Moves and Recent Developments
Chapter 7: Global Next Generation Cancer Diagnostics Market By Region
7.1 Overview
7.2. North America Next Generation Cancer Diagnostics Market
7.2.1 Historic and Forecasted Market Size by Segments
7.2.2 Historic and Forecasted Market Size By Type
7.2.2.1 qPCR & Multiplexing
7.2.2.2 Next Generation Sequencing
7.2.2.3 LOAC & RT-PCR
7.2.2.4 Other Technologies
7.2.3 Historic and Forecasted Market Size By Application
7.2.3.1 Therapeutic Monitoring
7.2.3.2 Companion Diagnostics
7.2.3.3 Prognostics
7.2.3.4 Cancer Screening
7.2.3.5 Risk Analysis
7.2.4 Historic and Forecast Market Size by Country
7.2.4.1 US
7.2.4.2 Canada
7.2.4.3 Mexico
7.3. Eastern Europe Next Generation Cancer Diagnostics Market
7.3.1 Historic and Forecasted Market Size by Segments
7.3.2 Historic and Forecasted Market Size By Type
7.3.2.1 qPCR & Multiplexing
7.3.2.2 Next Generation Sequencing
7.3.2.3 LOAC & RT-PCR
7.3.2.4 Other Technologies
7.3.3 Historic and Forecasted Market Size By Application
7.3.3.1 Therapeutic Monitoring
7.3.3.2 Companion Diagnostics
7.3.3.3 Prognostics
7.3.3.4 Cancer Screening
7.3.3.5 Risk Analysis
7.3.4 Historic and Forecast Market Size by Country
7.3.4.1 Russia
7.3.4.2 Bulgaria
7.3.4.3 The Czech Republic
7.3.4.4 Hungary
7.3.4.5 Poland
7.3.4.6 Romania
7.3.4.7 Rest of Eastern Europe
7.4. Western Europe Next Generation Cancer Diagnostics Market
7.4.1 Historic and Forecasted Market Size by Segments
7.4.2 Historic and Forecasted Market Size By Type
7.4.2.1 qPCR & Multiplexing
7.4.2.2 Next Generation Sequencing
7.4.2.3 LOAC & RT-PCR
7.4.2.4 Other Technologies
7.4.3 Historic and Forecasted Market Size By Application
7.4.3.1 Therapeutic Monitoring
7.4.3.2 Companion Diagnostics
7.4.3.3 Prognostics
7.4.3.4 Cancer Screening
7.4.3.5 Risk Analysis
7.4.4 Historic and Forecast Market Size by Country
7.4.4.1 Germany
7.4.4.2 UK
7.4.4.3 France
7.4.4.4 The Netherlands
7.4.4.5 Italy
7.4.4.6 Spain
7.4.4.7 Rest of Western Europe
7.5. Asia Pacific Next Generation Cancer Diagnostics Market
7.5.1 Historic and Forecasted Market Size by Segments
7.5.2 Historic and Forecasted Market Size By Type
7.5.2.1 qPCR & Multiplexing
7.5.2.2 Next Generation Sequencing
7.5.2.3 LOAC & RT-PCR
7.5.2.4 Other Technologies
7.5.3 Historic and Forecasted Market Size By Application
7.5.3.1 Therapeutic Monitoring
7.5.3.2 Companion Diagnostics
7.5.3.3 Prognostics
7.5.3.4 Cancer Screening
7.5.3.5 Risk Analysis
7.5.4 Historic and Forecast Market Size by Country
7.5.4.1 China
7.5.4.2 India
7.5.4.3 Japan
7.5.4.4 South Korea
7.5.4.5 Malaysia
7.5.4.6 Thailand
7.5.4.7 Vietnam
7.5.4.8 The Philippines
7.5.4.9 Australia
7.5.4.10 New Zealand
7.5.4.11 Rest of APAC
7.6. Middle East & Africa Next Generation Cancer Diagnostics Market
7.6.1 Historic and Forecasted Market Size by Segments
7.6.2 Historic and Forecasted Market Size By Type
7.6.2.1 qPCR & Multiplexing
7.6.2.2 Next Generation Sequencing
7.6.2.3 LOAC & RT-PCR
7.6.2.4 Other Technologies
7.6.3 Historic and Forecasted Market Size By Application
7.6.3.1 Therapeutic Monitoring
7.6.3.2 Companion Diagnostics
7.6.3.3 Prognostics
7.6.3.4 Cancer Screening
7.6.3.5 Risk Analysis
7.6.4 Historic and Forecast Market Size by Country
7.6.4.1 Turkiye
7.6.4.2 Bahrain
7.6.4.3 Kuwait
7.6.4.4 Saudi Arabia
7.6.4.5 Qatar
7.6.4.6 UAE
7.6.4.7 Israel
7.6.4.8 South Africa
7.7. South America Next Generation Cancer Diagnostics Market
7.7.1 Historic and Forecasted Market Size by Segments
7.7.2 Historic and Forecasted Market Size By Type
7.7.2.1 qPCR & Multiplexing
7.7.2.2 Next Generation Sequencing
7.7.2.3 LOAC & RT-PCR
7.7.2.4 Other Technologies
7.7.3 Historic and Forecasted Market Size By Application
7.7.3.1 Therapeutic Monitoring
7.7.3.2 Companion Diagnostics
7.7.3.3 Prognostics
7.7.3.4 Cancer Screening
7.7.3.5 Risk Analysis
7.7.4 Historic and Forecast Market Size by Country
7.7.4.1 Brazil
7.7.4.2 Argentina
7.7.4.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
Next Generation Cancer Diagnostics Scope:
|
Report Data
|
Next Generation Cancer Diagnostics Market
|
|
Next Generation Cancer Diagnostics Market Size in 2025
|
USD XX million
|
|
Next Generation Cancer Diagnostics CAGR 2025 - 2032
|
XX%
|
|
Next Generation Cancer Diagnostics Base Year
|
2024
|
|
Next Generation Cancer Diagnostics Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Abbott, Agilent Technologies, Almac Group, Cepheid, F. Hoffmann-La Roche Ltd, GE Healthcare, Genomic Health, Hologic, Illumina, Janssen Global Services, Koninklijke Philips N.V, Myriad Genetics, Novartis AG, Opko Health, PerkinElmer, Qiagen, Sysmex Corporation, Thermo Fisher Scientific.
|
|
Key Segments
|
By Type
qPCR & Multiplexing
Next Generation Sequencing
LOAC & RT-PCR
Other Technologies
By Applications
Therapeutic Monitoring
Companion Diagnostics
Prognostics
Cancer Screening
Risk Analysis
|
